Previously, NHE1 overexpression was shown to be present in treatment resistant breast cancer, and inhibition of NHE1 with cariporide induced sensitivity to doxorubicin, thus suggesting a therapeutic target [101]. The gene discussed is SLC9A1; the disease is breast cancer.